Jaseng Korean Medicine Hospital Elucidates Mechanism by Which Curcuma Root Inhibits Osteoclast Formation and Bone Loss

The Spine and Joint Research Institute at Jaseng Korean Medicine Hospital announced on July 6 that its research on the inhibitory effect of Curcuma Root on inflammatory bone loss and its therapeutic mechanism has been published in the SCI(E)-level international journal "Advanced Biology" (IF=3.2).

Jaseng Korean Medicine Hospital has previously demonstrated the clinical efficacy of its signature herbal medicine for spinal and joint disorders, Shinbaro, in treating numerous musculoskeletal patients with conditions such as disc herniation, spinal stenosis, and arthritis. This latest study elucidates the therapeutic mechanism by which Curcuma Root, a key herbal ingredient in Shinbaro, acts in an inflammatory bone loss environment to protect bones and joints. While bone loss commonly refers to the gradual deterioration of bone due to aging or menopause, inflammatory bone loss is a pathological phenomenon in which osteoclasts become excessively activated due to inflammatory responses, such as in rheumatoid arthritis or periodontitis, leading to rapid bone degradation.

In the experimental mice with bone inflammation induced by lipopolysaccharide (LPS) in the skull tissue, the surge of osteoclasts (purple) and bone erosions significantly decreased as the concentration of Guchuk (CR) extract administered increased, and at the highest concentration (CR-200), the condition was restored to a level similar to the normal control group (PBS). Jaseng Korean Medicine Hospital

The research team led by Dr. Jin Young Hong at the Spine and Joint Research Institute of Jaseng Korean Medicine Hospital conducted a study to clarify the mechanism by which Curcuma Root extract inhibits the formation of osteoclasts that destroy bone and prevents bone damage. The team utilized both in vitro models of osteoclasts derived from the bone marrow of experimental mice and animal models induced with inflammatory bone loss to analyze the effects of varying concentrations of Curcuma Root extract.

The study found that Curcuma Root extract effectively suppressed the formation of bone-resorbing osteoclasts. Osteoclasts, which are formed by the fusion of multiple cells, dissolve bone, and in models where inflammatory bone loss was induced, treatment with the highest concentration (200μg/mL) of Curcuma Root extract exhibited a potent inhibitory effect, with osteoclast formation being nearly absent. In addition, the expression of key proteins that promote osteoclast formation and activation was also reduced, confirming that Curcuma Root fundamentally inhibits the osteoclastogenesis process.

Furthermore, the team verified the effect of Curcuma Root extract in an animal experiment that recreated bone resorption by inducing inflammation in the skulls of mice.

The results showed that as the administered concentration of Curcuma Root extract increased, the number of osteoclasts decreased, and the area of bone damage caused by resorption was also significantly reduced. The expression of major proteins involved in bone destruction decreased in proportion to the increasing concentration of Curcuma Root extract.

The researchers also identified the main components of Curcuma Root extract and found that it contains 'protocatechuic acid'. This compound is a naturally occurring polyphenol found in fruits, vegetables, and medicinal plants, known for its antioxidant and anti-inflammatory properties, as well as its ability to inhibit osteoclast formation and bone resorption. The research team explained that this compound is likely to be one of the core active components contributing to the bone-protective effects of Curcuma Root extract.

Dr. Jin Young Hong, of the Spine and Joint Research Institute at Jaseng Korean Medicine Hospital, stated, "Through this study, we have scientifically confirmed that Curcuma Root, a key ingredient in Jaseng's signature prescription Shinbaro, can effectively suppress osteoclast formation and bone damage." He added, "We will continue follow-up research so that it can be developed as a new therapeutic candidate for osteoporosis and various inflammatory bone diseases in the future."

This content was produced with the assistance of AI translation services.